{"id":2921,"date":"2010-02-18T08:12:00","date_gmt":"2010-02-18T03:12:00","guid":{"rendered":"http:\/\/www.policymed.com\/five-part-podcast-series-on-fda-features-john-kamp-of-coalition-for-healthcare-communication\/"},"modified":"2010-02-18T08:12:00","modified_gmt":"2010-02-18T03:12:00","slug":"five-part-podcast-series-on-fda-features-john-kamp-of-coalition-for-healthcare-communication","status":"publish","type":"post","link":"https:\/\/www.policymed.com\/2010\/02\/five-part-podcast-series-on-fda-features-john-kamp-of-coalition-for-healthcare-communication.html","title":{"rendered":"Five Part Podcast Series on FDA Features John Kamp of Coalition for Healthcare Communication"},"content":{"rendered":"

\"\"<\/a><\/font><\/p>\n

A new five-part Podcast series was recently announced by Med Ad News editors Steven Niles and Joshua Slatko. The series will include discussions from John Kamp, JD, Executive Director of the Coalition for Healthcare Communication.  <\/span>The topics center on FDA policy and procedures.  <\/span>John served as a legal and policy advisor for the Federal Communications Commission and Senior Vice President of the American Association of Advertising Agencies.<\/font><\/p>\n

EPISODE 1: Tax Terror<\/o:p><\/font><\/strong><\/p>\n

Sponsored by CommonHealth, a WPP company<\/font><\/p>\n

This episode focuses on why eliminating the marketing expense tax exemption is still a popular idea in Washington, even though it was avoided in the healthcare reform bill.  <\/span><\/font><\/p>\n

Click here to download Episode 1<\/font><\/a><\/p>\n

The final four episodes will be released separately every two weeks:<\/font><\/p>\n

EPISODE 2: The New FDA<\/o:p><\/font><\/strong><\/p>\n

In this episode, John Kamp discusses his confidence in a new FDA lead by Commissioner Margaret Hamburg and Deputy Commissioner Joshua Sharfstein, and what it will mean for the healthcare industry.<\/font><\/p>\n

EPISODE 3: Don't Forget FDAAA<\/o:p><\/font><\/strong><\/p>\n

Mr. Kamp will discuss a number of provisions of the Food and Drug Administration Amendments Act of 2007 that have yet to see their full impact, including the growing importance of Risk Evaluation and Mitigation Strategies (REMS).<\/font><\/p>\n

EPISODE 4: Approach with Caution<\/o:p><\/font><\/strong><\/p>\n

After FDA's hearing on the pharmaceutical industry's use of social media last year, marketers are moving forward cautiously. John Kamp will discuss why legal departments will continue to voice strong resistance to going too far, while he also acknowledges the great opportunity social media holds in improving the industry's relationship and reputation with consumers.<\/font><\/p>\n

EPISODE 5: The Silver Lining<\/o:p><\/font><\/strong><\/p>\n

John Kamp discusses why communications companies could see an upswing in business as a number of factors take shape. A competent, confident FDA has the potential to open a wider approval window, bringing many new products to market. Healthcare reform has the potential to bring in many new patients demanding information about available medicines. And agreement between the pharmaceutical industry and government around the importance of patient adherence will expand opportunities for developing appropriate messaging.<\/font><\/p>\n

For each of these episodes we will try to provide summaries of the topics and issues discussed by Mr. Kamp. More information about Med Ad News <\/font>click here<\/font><\/a>. <\/font><\/p>\n","protected":false},"excerpt":{"rendered":"

A new five-part Podcast series was recently announced by Med Ad News editors Steven Niles and Joshua Slatko. The series will include discussions from John Kamp, JD, Executive Director of the Coalition for Healthcare Communication.  The topics center on FDA policy and procedures.  John served as a legal and policy advisor for the Federal Communications […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[744,85,169,576,187,1101,743,194,383,86],"class_list":["post-2921","post","type-post","status-publish","format-standard","hentry","category-fda","tag-faada","tag-fda","tag-food-and-drug-administration","tag-joshua-sharfstein","tag-margaret-hamburg","tag-new","tag-podcast","tag-rems","tag-risk-evaluation-and-mitigation-strategies","tag-social-media"],"_links":{"self":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/2921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/comments?post=2921"}],"version-history":[{"count":0,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/2921\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media?parent=2921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/categories?post=2921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/tags?post=2921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}